Real-world evidence studies designed to answer the question a decision-maker asked
Real-world evidence study design services from a clinician led team serving India, MENA, Europe, and global markets.
Real-world evidence (RWE) has moved from supporting actor to lead in many regulatory and access decisions, but a real-world study only carries weight if it was designed to answer a specific, pre-specified question with a method that controls the biases observational data invite. A registry, a claims analysis, or a chart review assembled without that discipline produces numbers that reviewers discount.
EvySaif designs and reports real-world evidence studies for regulatory, HTA, and medical affairs purposes: framing the research question, choosing the data source and study design, specifying the analysis before the data are touched, and reporting to the standards observational research is now held to. This complements our broader real-world evidence and outcomes research capability by focusing on the design and protocol stage where study credibility is won or lost.
Where RWE study design succeeds or fails
- Question first. The estimand, the target population, the exposure, the comparator, and the outcome are defined before the data source is chosen, so the study answers a decision-relevant question rather than whatever the data happen to allow.
- Design to control bias. Cohort, case-control, self-controlled, or target-trial-emulation designs are selected for the question, with confounding addressed through design and analysis rather than hoped away.
- Pre-specified analysis. A statistical analysis plan written before analysis begins is what separates evidence from data dredging, and reviewers increasingly ask to see it.
- Fit-for-purpose data. Claims databases, electronic health records, registries, and chart reviews each have strengths and blind spots; the source is matched to the question and its limitations reported honestly.
Reporting that reviewers accept
Observational studies are reported to STROBE, and database studies to the RECORD extension, with transparency about data provenance, cohort definitions, and sensitivity analyses. For studies intended to inform HTA submissions or feed a global value dossier, this reporting discipline is what lets the evidence travel from a standalone study into the access argument without being re-litigated.
What we deliver
RWE protocols and analysis plans
Pre-specified protocols and statistical analysis plans for observational studies, designed around a decision-relevant question.
Retrospective database studies
Claims and electronic health record analyses with transparent cohort definitions and bias control by design.
Prospective and registry studies
Observational study and registry designs, including post-market and PMCF-linked studies for devices.
RWE reporting
Study reports and manuscripts to STROBE and RECORD, ready for regulatory, HTA, or publication use.
Built to the standards that matter
Frequently asked questions
When is real-world evidence appropriate?
RWE suits questions that trials cannot answer practically or ethically: long-term outcomes, rare events, real-world effectiveness, treatment patterns, and comparative questions where a trial is infeasible. It is strongest when the question is defined before the data source is chosen.
How do you control for confounding in observational studies?
Through design (such as target trial emulation and appropriate comparator selection) and through analysis (such as adjustment, matching, or weighting), with the approach pre-specified and sensitivity analyses reported. No single method removes all bias, so we report the residual limitations honestly.
Can RWE support regulatory submissions?
Increasingly yes, where the study is designed and reported to the standard regulators expect. We design RWE studies with the intended regulatory or HTA use defined from the outset, which shapes the design choices.